Since its foundation in January 2021, PURMX Therapeutics has been developing MIRX002, a seed born from basic research at Hiroshima University, as its main focus.

​

First-in-human investigator-initiated clinical trials MIRX002-01 (single dose) and MIRX002-02 (multiple dose) are currently underway at Hiroshima University.

​

PURMX Therapeutics is the world's pioneer in the use of natural microRNAs as nucleic acid drugs, and has attracted much attention both in Japan and abroad, including a first-in-human investigator-initiated clinical trial soon after the company's establishment. MIRX002 has an anti-tumor spectrum that can be applied to other refractory cancers (including cancer stem cells and cancer cells resistant to anti-cancer drugs), and is a very promising seed that can be considered for expansion of indications in the same formulation.